Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11473 posts found.

FDA approves Vabysmo to treat vision-threatening retinal conditions

January 31, 2022 Sales and Marketing

The FDA has approved vabysmo (faricimab-svoa) for the treatment of neovascular or “wet” age-related macular degeneration and diabetic macular edema. …
News

Almirall announces licensing agreement to accelerate antibody drug discovery

January 31, 2022 Sales and Marketing

Almirall has announced a multi-target licensing agreement with Ablexis, focussed on licensing its AlivaMab Mouse technology, and a research collaboration …
News

Positive CHMP opinion for treatment of rare unpredictable disease

January 31, 2022 Sales and Marketing

Blueprint Medicines has announced that the CHMP has adopted a positive opinion recommending to expand the current indication for AYVAKYT® …
News

CHMP recommends approval of dupixent for children with severe asthma

January 31, 2022 Sales and Marketing

The EMA’s CHMP has adopted a positive opinion recommending the extension of the approval of Dupixent (dupilumab) for children with …
News

Ascletis begins Phase III trial into bevacizumab for treatment of recurrent glioblastoma

January 24, 2022 Sales and Marketing

Ascletis Pharma has announced the dosing of the first patient in the Phase III registration clinical trial of ASC40, combined …
News

Pfizer: Annual COVID shots preferable to frequent boosters

January 24, 2022 Sales and Marketing

Pfizer CEO Albert Bourla has commented that an annual COVID-19 vaccine would be preferable to more frequent booster shots in …
News

NICE expands guidance for lokelma in adult patients with persistent hyperkalaemia

January 24, 2022 Sales and Marketing

NICE have updated the Technology Appraisal Guidance (TAG) for Lokelma (sodium zirconium cyclosilicate SZC) in the treatment of adult patients …
News

Veklury obtains FDA approval for COVID-19 outpatients

January 24, 2022 Sales and Marketing

The FDA has granted expedited approval of a supplemental new drug application (sNDA) for Veklury (remdesivir) for he treatment of …
News

Neurimmune and Ono Pharmaceutical collaborate to research neurodegenerative diseases

January 17, 2022 Sales and Marketing

Neurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical. The companies aim to focus on creating …
News

NICE draft guidance recommends new treatment for rare liver condition

January 17, 2022 Sales and Marketing

On Friday 14 January, NICE published a final draft Highly Specialised Technologies guidance, recommending odevixibat in line with its marketing …
News

FDA places Alzheimer’s therapeutic IND Application on hold

January 17, 2022 Sales and Marketing

The FDA has placed a hold on the Investigational New Drug (IND) application for DNL919, indicating they will provide an …
News

COVID-19 self-isolation cut to five full days in England

January 17, 2022 Sales and Marketing

The minimum self-isolation period for people testing positive for COVID-19 in England has been cut from seven days to five …
News

Trial finds new CAR T-cell therapy is effective at killing cancer cells

January 10, 2022 Sales and Marketing

A Phase I clinical trial funded by the NIHR Invention for Innovation (i4i) programme, and supported by the NIHR UCLH …
News

European Commission approves Lumykras for lung cancer patients

January 10, 2022 Sales and Marketing

The European Commission (EC) has granted conditional marketing authorisation for Lyumykras (sotorasib), a first-in-class KRAS inhibitor, for the treatment of …
News

FDA approval of QUVIVIQ (daridorexant) for the treatment of insomnia

January 10, 2022 Sales and Marketing

Idorsia Ltd has announced the FDA approval of QUVIVIQ™ (daridorexant) 25 mg and 50 mg for the treatment of adult …
News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024